Valuation : Lexicon Pharmaceuticals, Inc.

Market Cap 890M 767M 726M 658M 1.23B 85.02B 1.24B 8.62B 3.32B 43.25B 3.34B 3.27B 137B P/E 2026 *
-11.9x
P/E 2027 * -10.7x
Enterprise Value 890M 767M 726M 658M 1.23B 85.02B 1.24B 8.62B 3.32B 43.25B 3.34B 3.27B 137B EV / Sales 2026 *
23.5x
EV / Sales 2027 * 44.7x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
10/09 Lexicon Pharmaceuticals, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11:20 AM
01/09 Lexicon Pharmaceuticals Announces Results from Post Hoc Soloist-Whf Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure CI
24/08 Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk DJ
24/08 Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 MT
07/08 Lexicon Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
07/08 Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06/08 Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss MT
06/08 Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M MT
27/07 Lexicon Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy CI
27/07 Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment MT
30/06 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark CI
30/06 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Index CI
30/06 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark CI
1 day-0.99%
1 week-10.71%
Current month-11.11%
1 month-17.70%
3 months+5.82%
6 months+16.28%
Current year+73.91%
1 week 1.95
Extreme 1.95
2.25
1 month 1.95
Extreme 1.95
2.48
Current year 1.1
Extreme 1.1
2.68
1 year 1.06
Extreme 1.06
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 08/07/2024
Director of Finance/CFO 59 02/01/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 83 01/01/2005
Chairman 71 27/02/2012
Director/Board Member 67 28/08/2007
Date Insider Type Main position Quantity % Market Cap. Importance
3/6/26 Exercice

Director

178,624 0.0402%
3/6/26 Exercice

Director

178,624 0.0402%
3/6/26 Exercice

Director

178,624 0.0402%
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%-10.71%+80.18%+31.58% 890M
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
+1.67%+2.47%-11.23%+388.34% 28.27B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
Average -0.92%-4.17%+40.55%+154.64% 27.12B
Weighted average by Cap. -0.84%-3.09%+33.61%+133.33%

Financials

2026 *2027 *
Net sales 37.95M 32.7M 30.96M 28.06M 52.64M 3.63B 52.91M 368M 141M 1.84B 143M 139M 5.83B 19.91M 17.16M 16.25M 14.73M 27.63M 1.9B 27.77M 193M 74.2M 968M 74.79M 73.15M 3.06B
Net income -72.44M -62.41M -59.1M -53.56M -100M -6.92B -101M -702M -270M -3.52B -272M -266M -11.13B -90.96M -78.37M -74.21M -67.26M -126M -8.69B -127M -881M -339M -4.42B -342M -334M -13.97B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
11/09/26 USD 2.000 -0.99% 3,726,759
10/09/26 USD 2.020 -6.05% 2,938,740
09/09/26 USD 2.150 -3.59% 2,204,341
08/09/26 USD 2.230 -0.45% 1,657,041
04/09/26 USD 2.240 -0.88% 1,044,611
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.000USD
Average target price
3.856USD
Spread / Average Target
+92.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!